The study medication, DONQ52, is an antibody (a protein found in the immune system). It is being developed as a potential celiac disease treatment. DONQ52 is designed to target a molecule known to cause celiac disease symptoms when gluten is ingested. This may protect the small intestine of a person with celiac disease.
You will be randomly assigned to receive either the study medication or placebo (no active ingredients). You have a 3 in 4 chance of receiving the study medication.
Investigational means the study medication is not approved by regulatory authorities like the US Food and Drug Administration (FDA), and it can only be used in clinical research studies like LILY.